<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article reviews the randomized control trials (RCT's) that were published in 2007 of emerging pharmacotherapies in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> (&lt;/= 2 weeks), sub-<z:hpo ids='HP_0011009'>acute</z:hpo> (2 to 12 weeks) and <z:hpo ids='HP_0011010'>chronic</z:hpo> (&gt;/= 12 weeks) <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A Medline search generated 22 RCT's in <z:hpo ids='HP_0001297'>stroke</z:hpo> in the year 2007 in the English language </plain></SENT>
<SENT sid="2" pm="."><plain>These trials were primarily efficacy studies </plain></SENT>
<SENT sid="3" pm="."><plain>These included the role of <z:chebi fb="0" ids="35664">statins</z:chebi> (an anti-<z:chebi fb="23" ids="18059">lipid</z:chebi> agent) in reducing post-<z:hpo ids='HP_0001297'>stroke</z:hpo> morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>; <z:chebi fb="105" ids="17234">glucose</z:chebi>-<z:chebi fb="120" ids="26216">potassium</z:chebi>-insulin infusion in hyperglyceamic <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients; <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (an anti-diabetic medication) to reduce recurrence of <z:hpo ids='HP_0001297'>stroke</z:hpo> in Type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one FDA approved thrombolytic agent (r <z:chebi fb="6" ids="15702,53394">TPA</z:chebi>); benefit of <z:chebi fb="8" ids="10033">warfarin</z:chebi> (an <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>) in elderly patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> in the community; NXY (a free radical trapping agent) and <z:chebi fb="1" ids="50694">minocycline</z:chebi> both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a <z:chebi fb="1" ids="38215">Calcium channel blocker</z:chebi>) in the prevention of vasospasm, and <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> to prevent hyponatraemia after sub-arachnoid <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Finally the role of non-pharmacotherapy like stents for patient's with <z:e sem="disease" ids="C0751815" disease_type="Disease or Syndrome" abbrv="">internal carotid artery dissection</z:e> with tandem internal carotid and middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and in vertebral <z:mp ids='MP_0006135'>artery stenosis</z:mp> </plain></SENT>
</text></document>